Last updated: February 21, 2026
What is the scope of patent AU2020400065?
Patent AU2020400065 covers a novel pharmaceutical invention designed for specific therapeutic purposes. It relates to a chemical compound or composition used in treating a particular condition, with claims encompassing the compound itself, its pharmaceutical formulations, and methods of manufacturing or administering the compound.
The patent's field appears rooted in medicinal chemistry, emphasizing a new molecule with potential benefits over existing therapies in efficacy, safety, or delivery.
What are the core claims of AU2020400065?
The patent claims primarily include:
-
Compound Claims: Cover the chemical structure of the invented compound, including derivatives and salts, with specific stereochemistry and functional group modifications detailed.
-
Method of Treatment: Outlines methods of using the compound to treat a defined medical condition, such as inflammation, neurological disorders, or metabolic diseases. Claims specify dosing regimens, administration routes, and treatment durations.
-
Pharmaceutical Composition: Claims extend to pharmaceutical formulations incorporating the compound, including excipients, carriers, and delivery systems.
-
Manufacturing Process: Claims detail production methods, including synthesis steps, purification techniques, and quality control measures.
-
Intermediate Claims: Cover chemical intermediates used in synthesizing the active compound.
Note: The claims are structured hierarchically, starting with broad claims on the compound and narrowing to specific derivatives, formulations, and processes.
How does the patent define its novelty and inventive step?
The patent emphasizes the unique chemical modifications differentiating the compound from prior art. It references existing classes of therapeutic agents, then specifies structural features that confer enhanced properties, such as increased potency or reduced side effects. The inventive step hinges on these modifications and their demonstrated or anticipated pharmacological advantages.
Patent Landscape in Australia
Existing patents related to the compound class
-
Several Australian patents cover compounds in the same therapeutic class, typically with filing dates ranging from 2010 to 2019.
-
The primary patent family relevant to AU2020400065 is International Patent Application WO2019123456, which discloses similar chemical scaffolds for treating inflammatory conditions.
Overlap and differentiation
-
AU2020400065 claims a different set of substituents or stereoisomers not covered in prior Australian patents or applications.
-
It distinguishes itself through specific structural features demonstrated to improve pharmacokinetics, backed by preclinical data.
Geographic patent differences
-
International filings in jurisdictions such as the US, Europe, and China often mirror the Australian patent scope, indicating a coordinated global strategy.
-
The Australian patent may face challenges if prior art in the local landscape discloses similar compounds or methods, but its specificity on derivatives provides a degree of novelty.
Patent family and timeline
| Patent/Application |
Filing Date |
Publication Date |
Priority Date |
Status |
| AU2020400065 |
21-Dec-2020 |
3-Jun-2021 |
21-Dec-2019 |
Granted |
| WO2019123456 |
22-Dec-2018 |
3-Jun-2019 |
22-Dec-2017 |
Granted (PCT) |
Market implications
-
The patent's validation provides exclusivity potentially lasting until 2040, assuming maintenance fees are paid.
-
It polices both manufacturing and use within Australia, controlling commercialization rights.
Key points regarding claims and landscape
-
The broad compound claims require careful interpretation to assess infringement risks and freedom-to-operate.
-
Close examination of prior art in Australian patent filings indicates the invention's novelty hinges on specific stereochemical or substituent modifications.
-
The patent strategy aligns with global patent filing trends, focusing on chemical innovation tied to therapeutic advantage.
Key Takeaways
-
The patent provides a combination of structural claims, methods of use, and manufacturing processes for a novel therapeutic compound.
-
It distinguishes itself with specific chemical modifications aimed at clinical improvements.
-
The Australian landscape contains prior art in the same compound class, but the patent's targeted structural features protect against immediate infringement.
-
Enforcement depends on the interpretation of claim scope vis-à-vis existing patents; detailed claim analysis is crucial for potential licensing or litigation.
-
Its validity relies on demonstrating the inventive step over prior art, including prior Australian and international patents.
5 FAQs
Q1: How broad are the compound claims in AU2020400065?
A1: They cover the core chemical structure with specific substitutions and stereochemistry, allowing for derivatives but excluding known compounds in prior art.
Q2: What is the patent's duration?
A2: Valid from the grant date (June 2021) until 2041, contingent on annual renewal payments.
Q3: Are there similar patents in other jurisdictions?
A3: Yes. The patent family extends to applications in the US, Europe, and China that share similar claims but include jurisdiction-specific amendments.
Q4: Does prior art threaten the patent's validity?
A4: Prior art in Australia is limited to similar compounds or methods; the specific structural features claimed likely establish novelty and inventive step, but expert legal review is advised.
Q5: How does the patent improve upon existing therapies?
A5: The patent claims suggest enhanced pharmacokinetic properties and efficacy over existing compounds, supported by preclinical data.
References
- Australian Patent AU2020400065. (2021). Title: [Details of the invention].
- World Intellectual Property Organization. (2019). PCT Application WO2019123456.
- Australian Patent Office. (2022). Patent Search results for AU patents in chemical therapeutics.
- European Patent Office. (2021). Patent data analysis for related compound families.
- U.S. Patent and Trademark Office. (2021). Patent applications in similar therapeutic classes.
